Pharmacogenomic Evaluation of Antihypertensive Responses in Induced Pluripotent Stem (iPS) Cells Study

Completed

• Conditions: Hypertension
• Interventions: Genetic: iPSC

• Registration Number: NCT01943383
• Lead Sponsor: University of Florida

Brief Summary

Patients enrolled in this study will have completed one of the parent studies "Pharmacogenomic Evaluation of Antihypertensive Responses" (PEAR-1 or PEAR-2) evaluating how well their blood pressure was controlled by medication. Patients in the current study will provide a single tube of blood which will be used to create adult stem cells that can be converted into other cell types, like heart or vasculature. Patients will not be asked to return for any follow up visits.

Detailed Description

If the patient decide to participate in this study, they will have 1 visit for the study that will include a blood draw. Upon arrival to the clinic, the study will be explained to the patient in detail. The patient will be asked at that time to sign this consent form. The patient will have the opportunity to ask questions and the research staff will answer those questions. If the patient decides to participate in this study and sign a consent form, then a blood sample will be collected from a vein in the arm. A total of 2 teaspoons full of blood will be drawn for the study.

During this visit, in addition to collecting a blood sample, patients will be asked about their medical history and medications they are currently taking, and will have their vital signs assessed, including blood pressure, pulse, and temperature.

Blood will be drawn by a trained nurse or a phlebotomist at a family medicine clinic in Gainesville, Florida. The blood sample will be further processed in laboratories at the University of Florida, for the establishment of iPS cells. iPS cells will retain the patient's genetic makeup which makes them useful for research. Several experiments will be conducted on these cells that will provide data that can be used to learn more about how genetic markers can lead to differences in blood pressure response to medicines. These cells will be used for up to 8 years.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2013-08
• Study First Submitted: 2013-08-27
• Study First Submitted QC: 2013-09-16
• Study First Posted: 2013-09-17
• Status Verified: 2018-05
• Primary Completion: 2018-05
• Study Completion: 2018-05
• Last Update Submitted: 2018-05-29
• Last Update Posted: 2018-05-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 21

Inclusion Criteria

• participation in the parent trial PEAR (201-2005) or PEAR2 (271-2010)
• assigned to a diuretic arm

Read More

Exclusion Criteria

• no participation in the parent trial PEAR (201-2005) or PEAR2 (271-2010)
• assigned to a beta blocker arm

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Diuretic	iPSC	Patients who received a diuretic drug during the parent trial are eligible for participation.

Primary Outcome Measures

Name	Time	Method
Cellular gene expression, cellular protein expression, and site directed mutagenesis of induced pluripotent stem cells in response to antihypertensive drugs.	8 years	iPSC cells will be used to model the mechanisms by which genetic differences influence responses to antihypertensive drugs. Potential methods included cellular gene expression, cellular protein expression, and site directed mutagenesis.

Trial Locations

Locations (1)

University of Florida; 🇺🇸 Gainesville, Florida, United States